Relevance of Doubtful (“Equivocal”) Late Patch-Test Readings

Carlson, Sean; Gipson, Katrina; Nedorost, Susan T.

doi:10.2310/6620.2010.09047

Cited by 23 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At any rate, assessment of clinical relevance cannot refer to future events. Therefore, even sensitizations of doubtful relevance should be disclosed to the patient in order to enable him/her to actively avoid these substances .…”

Section: Test Reading and Interpretation Of Test Reactions (Especiallmentioning

confidence: 99%

S3 guidelines: Epicutaneous patch testing with contact allergens and drugs – Short version, Part 1

Mahler

Nast

Bauer

et al. 2019

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Summary Epicutaneous patch testing is the diagnostic standard for the detection of allergic contact dermatitis. The present guidelines are aimed at residents and board‐certified physicians in the fields of dermatology and allergology as well as other medical specialties involved in establishing the indication for patch testing and its execution in patients with contact dermatitis and other forms of delayed‐type hypersensitivity. The target audience also includes other health care providers and insurance funds. Based on a systematic literature search and a formal consensus process (S3), the guidelines were developed by dermatologists in collaboration with pediatricians, occupational medicine physicians, nursing staff as well as patient representatives. The systematic methodological approach and appraisal of evidence upon which the recommendations are based are outlined in a separate method report that also contains evidence tables. The guidelines address general aspects of patch testing as well as medicolegal issues. The recommendations given relate to topics such as the indication for patch testing, informed patient consent, as well as the choice of test substances, test chambers and test site, duration of exposure, reading times and interpretation of test reactions. Furthermore, recommendations are provided with respect to endogenous and exogenous factors, specific patient groups (children, pregnant women, immunosuppressed individuals) as well as possible risks and adverse events associated with patch testing using contact allergens. Note: This publication is part 1 of the short version of the S3 guidelines for “Epicutaneous patch testing using contact allergens and drugs” (registry no. 013 – 018; date: March 20, 2019; valid until December 31, 2021). Part 2 of the short version will be published in the next issue. The long version of these guidelines can be accessed at http://www.awmf.org. The method report is available as online publication (https://www.awmf.org/leitlinien/detail/ll/013-018.html) and contains the evidence tables in its appendix.

show abstract

Section: Test Reading and Interpretation Of Test Reactions (Especiallmentioning

confidence: 99%

S3 guidelines: Epicutaneous patch testing with contact allergens and drugs – Short version, Part 1

Mahler

Nast

Bauer

et al. 2019

J Deutsche Derma Gesell

View full text Add to dashboard Cite

show abstract

“…In jedem Fall kann sich die Einschätzung der klinischen Relevanz nicht auf die Zukunft beziehen. Daher sollte auch eine Sensibilisierung unklarer Relevanz in die Patientenaufklärung zur Substanzmeidung einbezogen werden .…”

Section: Ablesung Der Testung Und Interpretation Von Testreaktionen (unclassified

S3‐Leitlinie: Durchführung des Epikutantests mit Kontaktallergenen und Arzneimitteln – Kurzfassung Teil 1

Mahler

Nast

Bauer

et al. 2019

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Zusammenfassung Der diagnostische Standard zum Nachweis einer bestehenden allergischen Kontaktdermatitis ist der Epikutantest. Die vorliegende Leitlinie richtet sich an Assistenz‐ und Fachärzte der Dermatologie, Allergologie und Ärzte weiterer Fachgruppen in Klinik und Praxis, die an der Indikationsstellung oder Durchführung von Epikutantests bei Patienten mit Kontaktekzemen und weiteren Spättypallergien beteiligt sind, sowie Kooperationspartner der Ärzteschaft (Fachberufe im Gesundheitswesen, Kostenträger). Die Leitlinie zur Durchführung des Epikutantests mit Kontaktallergenen wurde auf der Basis einer systematischen Literatursuche zu definierten Schlüsselfragen evidenzbasiert und im formellen Konsensusverfahren (S3) von Dermatologen unter Einbindung von Pädiatern, Arbeitsmedizinern, Assistenzpersonal und Patientenvertretern erstellt. Bezüglich der methodischen und inhaltlichen Arbeit, auf denen die Empfehlungen basieren, wird auf Methodenbericht und Evidenztabellen verwiesen. Die Leitlinie stellt allgemeine Aspekte der Epikutantestung sowie medizinrechtlicher Aspekte dar. Es werden Empfehlungen gegeben zur Indikationsstellung, Patientenaufklärung, Auswahl von Testsubstanzen und Kammersystemen, Expositionsort, ‐dauer und Ablesezeitpunkten, Interpretation von Testreaktionen, endogenen und exogenen Einflussfaktoren, Testung besonderer Personengruppen (Kinder, Schwangere, Immunsupprimierte) sowie Risiken und unerwünschten Nebenwirkungen bei der Durchführung des Epikutantests mit Kontaktallergenen.

show abstract

“…Notably, the 'pull test' is most useful for compounds that cause homogenous erythema with fine surface epidermal enhancement (wrinkling) [namely, PG, CAPB, and FRPs], as opposed to those that create poral reactions [patchy follicular reactions (eg: cobalt)]. Correct diagnosis of a 'doubtful' (equivocal) reaction is especially important in patients with impaired barriers, as they have lower irritancy thresholds [4,5].…”

Section: Techniquementioning

confidence: 99%